Indofarma Tbk PT
IDX:INAF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
126
126
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| ID |
|
Indofarma Tbk PT
IDX:INAF
|
390.5B IDR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
530.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
279.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.2B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.1B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
96.7B EUR |
Loading...
|
Market Distribution
| Min | -111 644.7% |
| 30th Percentile | 0% |
| Median | 6.1% |
| 70th Percentile | 12.9% |
| Max | 524 864.9% |
Other Profitability Ratios
Indofarma Tbk PT
Glance View
PT Indofarma Tbk is engaged in the pharmaceutical and healthcare businesses. The company is headquartered in Bekasi, Jawa Barat and currently employs 1,095 full-time employees. The company went IPO on 2001-04-17. The firm's business segment based on the products consists of the drug business segment and other medical equipment segment. The medical equipment segment consists of diagnostic and medical equipment. Its business segment based on geographical distribution area covers five regions consisting of Sumatra, Java, Kalimantan, Sulawesi and Bali, West Nusa Tenggara, and East Indonesia. Its products and services include generic drugs, over-the-counter and food, medical devices, non-medical devices and household health products. The firm carries out business activities to produce either alone or under cooperation for finished drug products, such as essential medicines, generic medicines with logos, generic medicines with trade names, traditional medicines, medical equipment, diagnostics, as well as food products, both related to health maintenance and improvement as well as health restoration.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Indofarma Tbk PT is -112.1%, which is above its 3-year median of -119.1%.
Over the last 3 years, Indofarma Tbk PT’s Operating Margin has decreased from -6.5% to -112.1%. During this period, it reached a low of -261.1% on Sep 30, 2024 and a high of -6.5% on Sep 30, 2022.